ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Translational Pharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1663348
Effectiveness and Safety of Esketamine in Laparoscopic Surgery Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Provisionally accepted- 1The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China
- 2Hohhot First Hospital, Hohhot, China
- 3Chifeng Municipal Hospital, Chifeng, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective Laparoscopic surgery is commonly performed, with perioperative treatments aimed at minimizing its impact on patients. Esketamine, known for its antidepressant mechanism, has gained attention as an anesthetic. This review evaluates its effectiveness and safety in laparoscopic surgery patients, since existing trials report conflicting results. Patients and Methods A systematic search across eight databases identified RCTs (Randomized Controlled Trials) on esketamine's effects in laparoscopic surgery patients. Outcomes assessed included VAS (Visual Analog Scale), AIS (Athens Insomnia Scale), NRS (Numeric Rating Scale), QoR-15 (Postoperative Quality of Recovery), remifentanil consumption, ICFS-10 (Inpatient Cognitive Function Scale) scores, and plasma BDNF (brain-derived neurotrophic factor) concentrations. The study is registered in PROSPERO (CRD42025630085). Results Fifteen studies involving 1,553 participants were included. Esketamine reduced postoperative VAS (SMD: -0.47; 95% CI [-0.89, -0.05]; P = 0.027) and NRS scores (SMD: -0.36; 95% CI [-0.70, -0.01]; P = 0.042). It also decreased AIS scores on the first (SMD: -0.55; 95% CI [-1.03, -0.07]; P = 0.026) and third days (SMD: -0.85; 95% CI [-1.42, -0.29]; P = 0.003), and ICFS-10 scores (first: SMD: -0.55; third: SMD: -0.62). Additionally, esketamine lowered remifentanil consumption (SMD: -0.58; P = 0.003) and infusion rate (SMD: -0.40; P = 0.001), while increasing plasma BDNF concentrations (SMD: 1.19; P = 0.044). Sensitivity analysis confirmed the stability of these results. Conclusion Esketamine alleviates postoperative pain, reduces remifentanil and opioid consumption, improves sleep quality and recovery, mitigates postoperative fatigue, and increases plasma BDNF concentrations in laparoscopic surgery patients. Nevertheless, this meta-analysis still has certain limitations, most notably the high heterogeneity of the studies incorporated and the limited geographical coverage of the research sites. Further studies are needed to confirm these findings and support its use in improving perioperative outcomes.
Keywords: Esketamine, laparoscopic surgery, Meta-analysis, randomized controlled trial, Perioperative Period
Received: 10 Jul 2025; Accepted: 06 Oct 2025.
Copyright: © 2025 Wang, Hao, Fan, Wu and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Lifang Wu, otfat1024830@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.